María Alejandra Egui Rojo1, Ignacio Moncada Iribarren2, Joaquín Carballido Rodriguez3, Juan Ignacio Martinez-Salamanca4. 1. Urology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain. 2. Department of Urology, Hospital de la Zarzuela, Madrid, Spain. 3. Department of Urology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. 4. Department of Urology, Hospital Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, C/ Manuel de Falla no. 1, Majadahonda 28222, Madrid, Spain.
Abstract
INTRODUCTION: Peyronie's disease (PD) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. In most cases, PD is accompanied by a physical and psychological impact. Xiaflex® is an injectable collagenase clostridium histolyticum (CCh) preparation consisting of a predetermined mixture of two distinct collagenases. Recently the US Food and Drug Administration (FDA) approved Xiaflex® for the nonsurgical treatment of men with PD with curvature of 30° or more and tangible scar tissue plaque in their penis. METHOD: This article presents a comprehensive review of the updated information on the use of Xiaflex® for the nonsurgical treatment of PD. RESULTS: Mean improvements in penile curvature ranging from 29% to 34% and in bother domain scores have been reported. The majority of the reported adverse effects are mild or moderate and 79% resolve without intervention. CONCLUSION: The combined results of these trials have led to the FDA approval of CCh for the treatment of PD. However, the long-term effects and results need further investigation, with large follow-up series. Considering these results, future perspectives will probably result in the use of a combined or sequential therapy including CCh.
INTRODUCTION:Peyronie's disease (PD) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. In most cases, PD is accompanied by a physical and psychological impact. Xiaflex® is an injectable collagenase clostridium histolyticum (CCh) preparation consisting of a predetermined mixture of two distinct collagenases. Recently the US Food and Drug Administration (FDA) approved Xiaflex® for the nonsurgical treatment of men with PD with curvature of 30° or more and tangible scar tissue plaque in their penis. METHOD: This article presents a comprehensive review of the updated information on the use of Xiaflex® for the nonsurgical treatment of PD. RESULTS: Mean improvements in penile curvature ranging from 29% to 34% and in bother domain scores have been reported. The majority of the reported adverse effects are mild or moderate and 79% resolve without intervention. CONCLUSION: The combined results of these trials have led to the FDA approval of CCh for the treatment of PD. However, the long-term effects and results need further investigation, with large follow-up series. Considering these results, future perspectives will probably result in the use of a combined or sequential therapy including CCh.
Authors: Martin Gelbard; Larry I Lipshultz; James Tursi; Ted Smith; Greg Kaufman; Laurence A Levine Journal: J Urol Date: 2012-04-13 Impact factor: 7.450
Authors: David Gilpin; Stephen Coleman; Stephen Hall; Anthony Houston; Jeff Karrasch; Nigel Jones Journal: J Hand Surg Am Date: 2010-12 Impact factor: 2.230
Authors: Martin Gelbard; Irwin Goldstein; Wayne J G Hellstrom; Chris G McMahon; Ted Smith; James Tursi; Nigel Jones; Gregory J Kaufman; Culley C Carson Journal: J Urol Date: 2013-01-31 Impact factor: 7.450
Authors: Juan I Martínez-Salamanca; Alejandra Egui; Ignacio Moncada; Javier Minaya; Claudio Martínez Ballesteros; Luis Del Portillo; Ignacio Sola; Joaquín Carballido Journal: J Sex Med Date: 2013-11-22 Impact factor: 3.802
Authors: Christian J Nelson; Chris Diblasio; Muammer Kendirci; Wayne Hellstrom; Patricia Guhring; John P Mulhall Journal: J Sex Med Date: 2008-06-28 Impact factor: 3.802